Jyothy Labs sets Rs 147 crore buyback at Rs 215 per share

Jyothy Labs Limited approved a Rs 147 crore tender-offer buyback at Rs 215 per share in Q2 FY27, with promoters, the promoter group and persons in control opting out. Jyothy Labs said the decision reflects confidence in its brands and financial position, which included approximately Rs 846 crore in cash and zero debt.

What are Jyothy Labs' buyback terms?

Jyothy Labs has approved a Rs 147 crore share buyback through the tender-offer route at Rs 215 per share. Management disclosed the Board decision during its Q2 FY27 earnings call, but did not provide a buyback timetable, the number of shares proposed for repurchase, or an expected acceptance ratio.

The tender route makes participation subject to applicable regulations, as management stated in the Q2 FY27 call. Management said its Rs 147 crore proposal followed its assessment that the prevailing market valuation did not adequately reflect the company’s brands, growth potential and financial position; this was management’s view, not a disclosed valuation calculation.

The Rs 215 offer price and Rs 147 crore maximum size sit alongside Jyothy Labs’ stated dividend payout policy of 35% to 50% of profit. Management also said profitable organic growth remains the priority and that the company will continue to evaluate complementary acquisition opportunities.

Who can participate in Jyothy Labs' buyback?

Eligible public shareholders may participate in Jyothy Labs’ Rs 147 crore tender offer because promoters, the promoter group and persons in control will not participate. Management said this structure allows eligible public shareholders to benefit, subject to the regulations applicable to the tender process.

The Q2 FY27 call does not state how many public shares could be tendered or how many shares may be accepted. The Rs 147 crore approval therefore sets the aggregate buyback amount, while participation and acceptance depend on the process and regulations that management did not detail in the transcript.

Promoter non-participation comes alongside the Rs 846 crore cash balance and zero debt reported in the Q2 FY27 update. Management said the debt-free balance sheet provides flexibility to support growth priorities, rather than indicating that the Rs 147 crore buyback would require borrowing.

Why did Jyothy Labs approve the buyback during Q2 FY27?

Jyothy Labs approved the buyback while reporting continued underlying growth but sharply lower profitability in Q2 FY27. Revenue from operations rose 3.3% year on year to Rs 760 crore, while reported volume declined marginally after the Pril and Fa brand licence agreement expired in May 2026.

Excluding Pril and Fa, Jyothy Labs reported 12.4% Q2 FY27 value growth and 8.1% volume growth. For H1 FY27, the corresponding underlying value and volume growth were 10.2% and 6.2%, compared with reported revenue growth of 3.1% to Rs 1,533 crore and a marginal reported volume decline.

Management linked the Rs 147 crore buyback to confidence in long-term fundamentals while acknowledging a difficult commodity environment. Gross margin declined to 34.8% in Q2 FY27 from 48.1% a year earlier and 38.5% in the preceding quarter, as crude derivatives, chemicals and packaging costs increased.

Operating earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 19 crore in Q2 FY27, resulting in a 2.5% operating EBITDA margin against 16.1% a year earlier. Profit after tax was Rs 10.6 crore, and management said this level of profitability was significantly below its expectations.

How does Jyothy Labs plan to restore profitability?

Jyothy Labs plans a progressive margin recovery through selective pricing, grammage adjustments, procurement efficiencies, value engineering, product-mix changes and cost discipline. Management said it took pricing actions of about 4% during Q2 FY27, but those actions did not fully offset the increase in input costs.

According to the chief financial officer, raw-material and packaging-material inflation contributed close to an 18% year-on-year impact in Q2 FY27. About 4% of sales-price increases and some mix benefit partly offset that effect, leaving a gross-margin impact of about 13% to 13.5%; management said pricing alone cannot bridge the full gap.

Commodity exposure is central to the Q2 FY27 margin pressure because management said 60% to 65% of Jyothy Labs’ consumption basket is linked to crude derivatives. High-density polyethylene, or HDPE, and polypropylene prices were about 55% to 60% above levels prevailing before the West Asia conflict, while packaging represented about 18% to 20% of the cost base.

Category mix is another management lever, with Fabric Care recording 10.4% value growth and liquid detergents growing by more than 50% year on year in Q2 FY27. Exo dishwash grew 23%, but management said liquid detergents currently carry lower margins than powder detergents because the category is still scaling and requires investment in consumer conversion.

Can Jyothy Labs fund growth plans after the buyback?

Jyothy Labs said its Rs 846 crore cash balance and zero debt allow it to continue growth investments after the Rs 147 crore buyback. Management reiterated in Q2 FY27 that profitable organic growth remains the priority, alongside its 35% to 50% dividend payout policy and review of complementary acquisitions.

The Q3 plan includes supporting Fabric Care, particularly liquid detergents and fabric conditioners, and building on Exo’s momentum. In Home Insecticides, or HI, management intends to improve profitability through product mix and newer formats including Maxo Agarbatti, after coil contribution fell to 30% to 35% of the HI portfolio from 43% to 45% a year earlier.

Working capital increased to 23 days in September 2026 from 15 days in March, primarily because material-cost inflation raised inventory values while inventory volumes remained broadly stable. Management expects working capital to gradually return to its 18-to-20-day medium range as conditions stabilise.

For Q3 FY27, management expects healthy underlying growth led by Fabric Care and new products, but said gross margins are likely to remain under pressure. It cannot assume a full H2 FY27 gross-margin recovery unless commodity prices moderate and remain stable, leaving the timing of improvement unresolved.

Conclusion

The Rs 147 crore buyback at Rs 215 per share combines Jyothy Labs’ capital return with management’s stated confidence in its brands, growth potential and debt-free balance sheet. Promoter non-participation limits tender participation to eligible public shareholders, while Q2 FY27 underlying value growth of 12.4% excluding Pril and Fa contrasted with a decline in operating EBITDA margin to 2.5%.

The next issue to watch is whether Q3 FY27 pricing, procurement, value engineering and mix actions begin to reduce the 13% to 13.5% gross-margin impact identified by management in Q2 FY27. Management also expects working capital to move gradually from 23 days in September 2026 toward its 18-to-20-day medium range, while linking margin recovery to stable commodity prices.